Serotonin and depression: A disconnect between the advertisements and the scientific literature

PLoS Medicine

Volumn 2, Issue 12, 2005, Pages 1211-1216

  Lacasse, Jeffrey R ^a   Leo, Jonathan ^b  

^a FLORIDA STATE UNIVERSITY   (United States)

^b LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; PAROXETINE; REBOXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; ANTIDEPRESSANT AGENT;

BEHAVIOR; CLINICAL TRIAL; CONSUMER; DEPRESSION; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH CARE; HUMAN; HYPERICUM PERFORATUM; MEDICAL LITERATURE; MEDICAL PRACTICE; MEDICAL RESEARCH; MENTAL DISEASE; NEUROTRANSMISSION; OBSESSIVE COMPULSIVE DISORDER; PREMENSTRUAL DYSPHORIC DISORDER; PSYCHIATRIC DIAGNOSIS; REVIEW; SOCIAL PHOBIA; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; ADVERTIZING; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED STATES;

ADVERTISING AS TOPIC; ANTIDEPRESSIVE AGENTS; CONSUMER PARTICIPATION; DEPRESSION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 29644436010     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0020392     Document Type: Review

References (60)

1. Mintzes B (2002) For and against: Direct to consumer advertising is medicalising normal human experience: For. BMJ 324: 908-909.
2. International Marketing Services Health (2004) Year-end U.S. Prescription and sales information and commentary. Fairfield (Connecticut): International Marketing Services Health Available: http://www.imshealth.com/ims/portal/front/ articleC/0,2777,6599_3665_69890098,00.html. Accessed 14 October 2005.
3. Donohue J, Berndt E (2004) Effects of direct-to-consumer advertising on medication choice: The case of antidepressants. J Pub Pol Marketing 23: 115-127.
4. United Kingdom Parliament (2005) House of Commons health report. London: United Kingdom House of Commons. Available: http://www.publications.parliament. uk/pa/cm200405/cmselect/cmhealth/42/4202.htm. Accessed 14 October 2005.
5. Pfizer (2004 March) Zoloft advertisement. Burbank (California): NBC.
6. Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: A review of supporting evidence. J Neuropsychiatry Clin Neurosci 7: 524-533.
7. Coppen A (1967) The biochemistry of affective disorders. Br J Psychiatry 113: 1237-1264.
8. Roggenbach J, Müller-Oerlinghausen B, Franke L (2002) Suicidality, impulsivity, and aggression-Is there a link to 5HIAA concentration in the cerebrospinal fluid? Psychiatry Res 113: 193-206.
9. Heninger G, Delgado P, Charney D (1996) The revised monoamine theory of depression: A modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 29: 2-11.
10. Mendels J, Stinnett J, Burns D, Frazer A (1975) Amine precursors and depression. Arch Gen Psychiatry 32: 22-30.
11. Horgan J (1999) The undiscovered mind: How the human brain defies replication, medication, and explanation. New York: Free Press. 336 p.
12. Murphy DL, Andrews AM, Wichems CH, Li Q, Tohda M, et al. (1998) Brain serotonin neurotransmission: An overview and update with emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. J Clin Psychiatry 59: 4-12.
13. Kirsch I, Moore TJ, Scoboria A, Nicholls SS (2002) The emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev Treat 5: article 23. Available: http://journals.apa.org/prevention/volume5/pre0050023a.html. Accessed 14 October 2005.
14. Kirsch I, Scoboria A, Moore TJ (2002) Antidepressants and placebos: Secrets, revelations, and unanswered questions. Prev Treat 5: article 33. Available: http://journals.apa.org/prevention/volume5/pre0050033r.html. Accessed 14 October 2005.
15. Moncrieff J, Wessely S, Hardy R (2005) Active placebos versus antidepressant for depression. Cochrane Database Syst Rev 2004: CD003012.
16. Geddes J, Freemantle N, Mason J, Eccles M, Boynton J (2005) Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression. Cochrane Database Syst Rev 2000: CD002791.
17. Karvoussi R, Segraves R, Hughes A, Ascher J, Johnston J (1997) Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 12: 532-537.
18. Schatzberg A (2000) Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 61 (Suppl 10): 31-38.
19. Szegedi A, Kohnen R, Dienel A, Kieser M (2005) Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): Randomised controlled double-blind non-inferiority trial versus paroxetine. BMJ 330: 503.
20. Hypericum Depression Trial Study Group (2002) Effect of Hypericum perforatum (St John's wort) in major depressive disorder: A randomized controlled trial. JAMA 287: 1807-1814.
21. Blumenthal J, Babyak M, Moore K, Craighead W, Herman S, et al. (1999) Effects of exercise training on older patients with major depression. Arch Intern Med 159: 2349-2356.
22. GlaxoSmithKline (2005) What does Paxil treat. London: GlaxoSmithKline. Available: http://www.paxil.com/about/ab_trt.html. Accessed 2005 14 October 2005.
23. Pfizer (2002) Zoloft for PMDD. Cambridge (Massachusetts): Pfizer. Available: http://zoloftforpmdd.about.com/. Accessed 14 October 2005.
24. Healy D (2002) The creation of psychopharmacology. Cambridge: Harvard University. 313 p.
25. Dubvosky S, Davies R, Dubvosky A (2003) Mood disorders. In: Hales R, Yudofsky S, editors. The American psychiatric textbook of clinical psychiatry, 4th ed. Washington (D.C.): American Psychiatric Press. pp. 439-542.
26. Consumer Reports (2003) Free rein for drug ads. Yonkers (New York): Consumer Reports Available: http://www.consumerreports.org/main/detailv2.jsp? CONTENT%3C%3Ecnt_id=299631&FOLDER%3C%3Efolder_id=162687. Accessed 14 October 2005.
27. United States General Accounting Office (2002) Prescription drugs: FDA oversight of direct-to-consumer advertising has limitations. Washington (D.C.): United States General Accounting Office. Available: http://www.gao.gov/new. items/d03177.pdf. Accessed 2005 February 19.
28. Mintzes B, Barer ML , Kravitz RL, Basett K, Lexchin J, et al. (2003) How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ 169: 405-412.
29. O'Brien C (2003 October 5) Drug firm to drop non-addiction claim. Irish Times.
30. GlaxoSmithKline (2005) Paxil Prescribing Information. Research Triangle Park (North Carolina): GlaxoSmithKine. Available: http://us.gsk.com/products/ assets/us_paxil.pdf. Accessed 14 October 2005.
31. Castren E (2005) Is mood chemistry? Nat Rev Neuroscience 6: 241-226.
32. Food and Drug Administration (2005) Code of federal regulations, 21CFR202. Title 21-Food and drugs. Chapter I-Food and drug administration. Department of Health and Human Services. Part 202-Prescription-drug advertisements. Available: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/ cfcfr/CFRSearch.cfm?CFRPart=202&showFR=1. Accessed 14 October 2005.
33. Pfizer (2005) Learning about depression: What causes depression. Cambridge (Massachusetts): Pfizer. Available: http://www.zoloft.com/zoloft/ zoloft.portal?_nfpb=true&_pageLabel=depr_causes Accessed 17 October 2005.
34. Food and Drug Administration Division of Drug Marketing, Advertising, and Communications (1997) Effexor warning letter. Rockville (Maryland): Food and Drug Administration. Available: http://www.fda.gov/cder/warn/june97/effexor.pdf. Accessed 14 October 2005.
35. Food and Drug Administration Division of Drug Marketing Advertising, and Communications (1998) Paxil warning letter. Rockville (Maryland): Food and Drug Administration. Available: http://www.fda.gov/cder/warn/mar98/6383.pdf. Accessed 14 October 2005.
36. Food and Drug Administration Division of Drug Marketing, Advertising, and Communications (1999) Remeron warning letter. Rockville (Maryland): Food and Drug Administration. Available: http://www.fda.gov/cder/warn/jan99/6950.pdf. Accessed 2005 May 9.
37. Food and Drug Administration Division of Drug Marketing, Advertising, and Communications (2000) Sarafem warning letter. Rockville (Maryland): Food and Drug Administration. Available: http://www.fda.gov/cder/warn/nov2000/dd9523.pdf. Accessed 14 October 2005.
38. Food and Drug Administration Division of Drug Marketing, Advertising, and Communications (2000) Effexor warning letter. Rockville (Maryland): Food and Drug Administration. Available: http://www.fda.gov/cder/warn/oct2000/dd8741.pdf. Accessed 14 October 2005.
39. Food and Drug Administration Division of Drug Marketing, Advertising, and Communications (2000) Remeron warning letter. Rockville (Maryland): Food and Drug Administration. Available: http://www.fda.gov/cder/warn/apr2000/dd8496.pdf. Accessed 14 October 2005.
40. Food and Drug Administration Division of Drug Marketing, Advertising, and Communications (2002) Celexa warning letter. Available: http://www.fda.gov/ cder/warn/2002/10853Celexa.pdf. Accessed 14 October 2005.
41. Food and Drug Administration Division of Drug Marketing, Advertising, and Communications (2004) Effexor warning letter. Rockville (Maryland): Food and Drug Administration. Available: http://www.fda.gov/cder/warn/2004/Effexor.pdf. Accessed 14 October 2005.
42. Food and Drug Administration Division of Drug Marketing, Advertising, and Communications (2004) Paxil warning letter. Rockville (Maryland): Food and Drug Administration. Available: http://www.fda.gov/cder/warn/2004/MACMIS12439.pdf. Accessed 14 October 2005.
43. Food and Drug Administration Division of Drug Marketing, Advertising, and Communications (2005) Zoloft warning letter. Rockville (Maryland): Food and Drug Administration. Available: http://www.fda.gov/cder/warn/2005/zoloft_letter. pdf. Accessed 14 October 2005.
44. Stahl SM (2000) Essential psychopharmacology: Neuroscientific basis and practical applications. Cambridge: Cambridge University Press. 601 p.
45. Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, et al. (2005) Influence of patients' requests for direct-to-consumer advertised antidepressants: A randomized controlled trial. JAMA 293: 1995-2002.
46. Kramer TAM (2002) Endogenous versus exogenous: Still not the issue. MedGenMed 4. Available: http://www.medscape.com/viewarticle/418269. Accessed 14 October 2005.
47. Angell M (2004) The truth about the drug companies: How they deceive us and what to do about it. New York: Random House. 336 p.
48. DeRubeis R, Hollon S, Amsterdam J, Shelton R, Young P, et al. (2005) Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 62: 409-416.
49. Hollon MF (2004) Direct-to-consumer marketing of prescription drugs: A current perspective for neurologists and psychiatrists. CNS Drugs 18: 69-77.
50. Valenstein ES (1998) Blaming the brain: The truth about drugs and mental health. New York: Free Press. 292 p.
51. Glenmullen J (2001) Prozac backlash: Overcoming the dangers of prozac, zoloft, paxil and other antidepressants with safe, effective alternatives. New York: Simon and Schuster. 384 p.
52. Delgado P, Moreno F (2000) Role of norepinephrine in depression. J Clin Psychiatry 61 (Supple 1): 5-11.
53. Kramer P (2002 July 7) Fighting the darkness in the mind, July 7. The New York Times. Sect 4: 8.
54. Lacasse JR, Gomory T (2003) Is graduate social work education promoting a critical approach to mental health practice? J Soc Work Educ 39: 383-408.
55. Healy D (2004) Let them eat prozac: The unhealthy relationship between the pharmaceutical companies and depression. New York: New York University. 351 p.
56. Kendler KS (2005) Toward a philosophical structure for psychiatry. Am J Psychiatry 162: 433-440.
57. Forest Pharmaceuticals (2005) Frequently asked questions. New York: Forest Pharmaceuticals. Available: http://www.celexa.com/Celexa/faq.aspx. Accessed 17 October 2005.
58. Forest Pharmaceuticals (2005) How Lexapro (escitalopram) works. New York: Forest Pharmaceuticals. Available: http://www.lexapro.com/english/ about_lexapro/how_works.aspx. Accessed 17 October 2005.
59. Eli Lilly (1998 January) Prozac advertisement. People Magazine: 40.
60. GlaxoSmithKline (2001 October) Paxil advertisment. Newsweek: 61.